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syndromes (ACS), represent the leading cause of
morbidity and mortality globally.1,2 Large-scale random-
ized trials and systematic reviews have established the
efﬁcacy and safety of several interventions for the
management of patients with ACS, including antiplatelet
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Open access under the Elsevier OA license .  patients with ST-segment elevation myocardial infarction
(MI), and secondary prevention with β-blockers, statins,
and angiotensin-converting enzyme inhibitors.3-7 Never-
theless, registries have consistently demonstrated that
the translation of such research ﬁndings into clinical
practice is suboptimal.8,9 The reasons for this gap
between evidence and practice are complex and include
barriers related to knowledge (lack of awareness and
familiarity), behavior (external barriers), and attitudes
(lack of agreement with current evidence, outcome
expectancy, and the inertia of previous practices in
changing behavior).10
Prior studies have demonstrated that certain quality
improvement strategies are associated with better quality
of care. These include reminder systems, academic
detailing (educational outreach visits), audit and feed-
back, case management, and distribution of educational
materials to health care providers.11 Combined strategies
targeting different barriers are more likely to be effective
Figure 1
Study design.
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ment interventions have rarely been rigorously evaluated.
We designed a cluster-randomized trial, Brazilian
Intervention to Increase Evidence Usage in Acute
Coronary Syndromes (BRIDGE-ACS), to assess the effec-
tiveness of a quality improvement initiative in patients
with ACS. The study has important features such as
concealed randomization (including reminders and dis-
tribution of educational materials and case management
at the professional practice or health care organization
level, which represents an ideal design for evaluating
dissemination and implementation strategies13) and
evaluation of the use of evidence-based ACS treatment
and the impact on patient outcomes.Methods
Study design and objectives
BRIDGE-ACS was a pragmatic 2-arm, cluster-randomized
(concealed), controlled trial (Figure 1) with blinded adjudica-
tion of outcomes and intention-to-treat analysis. The main
objective was to evaluate whether a multifaceted quality
improvement intervention can improve the prescription of
proven efﬁcacious therapies for patients with ACS within the
ﬁrst 24 hours and at hospital discharge and reduce the incidence
of major cardiovascular events.Participants
Cluster eligibility criteria and recruitment. Clus-
ters were eligible for the BRIDGE-ACS trial if they were general
teaching or nonteaching tertiary public hospitals from major
urban areas with an emergency department (ED) that receives
patients with ACS (Table I). We excluded private hospitals,
public cardiology institutes, and hospitals located in rural areas.
A list of potential eligible clusters was provided by the Brazilian
Ministry of Health. Letters were sent to eligible hospitals inviting
them to participate; hospitals not responding to 2 letters were
contacted by telephone.
Patient eligibility criteria and recruitment. At
each participating cluster, all consecutive eligible patients with
ACS were enrolled according to the following standardized
deﬁnitions (Table I)15:
• ST-segment elevation myocardial infarction (STEMI): New
or presumed new ST-segment elevation seen in any location
or new left bundle-branch block on the index or qualifying
electrocardiogram (ECG) with at least 1 positive cardiac
biochemical marker of necrosis (including troponin).
• Non–ST-segment elevation myocardial infarction
(NSTEMI): Presence of at least 1 positive cardiac biochemical
marker of necrosis without new ST-segment elevation seen
on the index or qualifying ECG.
• Unstable angina (UA): Absence of ST-segment elevation on
the ECG and serum biochemical markers indicative of
myocardial necrosis within each hospital laboratory's
Table I. Eligibility criteria
Participants
Cluster eligibility criteria and recruitment
Inclusion criteria
General teaching or nonteaching tertiary public hospitals from capitals
or major urban areas with an ED that typically assists patients with ACS
Exclusion criteria
Private for-profit or not-for-profit hospitals, public cardiology institutes,
and hospitals located in rural areas
Patients eligibility criteria and recruitment
Inclusion criteria
STEMI: new or presumed new ST-segment elevation seen in any
location or new LBBB on the index or qualifying ECG with at least 1
positive cardiac biochemical marker of necrosis (including troponin)
NSTEMI: presence of at least 1 positive cardiac biochemical marker of
necrosis without new ST-segment elevation seen on the index or
qualifying ECG
Unstable angina: absence of ST-segment elevation on the ECG and serum
biochemical markers indicative of myocardial necrosis within each
hospital laboratory's normal range, but with a discharge diagnosis of
ACS; patients originally admitted for unstable angina but in whom MI
occurred during the hospital stay were classified as having an MI
Exclusion criteria
Patients transferred from others hospitals within more than 12 hours and
for whom the presumptive admission diagnosis was ACS but were
subsequently shown to have some other cardiac or noncardiac cause
for their presentation
LBBB, Left bundle-branch block.
Figure 2
Reminder of “chest pain” patient enrolled in study.
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Patients originally admitted for unstable angina but in
whom MI occurred during the hospital stay were classiﬁed
as having an MI.
Centers were instructed to enroll patients as soon as they
presented in the ED. We excluded patients transferred from
other hospitals within N12 hours, patients with non–type I MIs,
and patients for whom the presumptive admission diagnosis was
ACS but were subsequently shown to have some other cardiac
or noncardiac cause for their presentation.Randomization and allocation concealment
Eligible clusters were randomly allocated (1:1) to a multifac-
eted quality improvement intervention (experimental group) or
to routine practice (control group). Randomization was
stratiﬁed by the following characteristics: teaching versus
nonteaching hospitals, presence or absence of a 24-hour cardiac
catheterization laboratory, and capability for cardiac surgery. To
guarantee concealment of allocation, all clusters were random-
ized at once by a blinded statistician using a central Web-based
randomization system developed by the Research Institute HCor
(São Paulo, Brazil).Blinding
Because of the nature of the intervention in the BRIDGE-ACS
trial, only the independent outcome assessors were blinded to
the intervention.Quality improvement intervention
The multifaceted quality improvement intervention included
reminders, a checklist, case management, and educational
materials implemented during a 6-month period. Clusters
randomized to receive the quality improvement intervention
received on-site training visits complemented by Web-based and
telephone training. In addition, 2 health care providers from all
clusters (a physician who acted as the local leader and a nurse
who acted as case manager) attended a 2-day workshop on how
to implement the BRIDGE-ACS quality improvement interven-
tion. These training sessions used simulation-based learning
techniques. These 2 professionals trained the health care staff
involved with the care of ACS patients at their site, provided
formal documentation of training sessions to the coordinating
center, and guaranteed adequate implementation of the quality
improvement tools. At least 80% of the research medical staff
from each site were trained for this study.
Reminders and checklist. The reminders and the
checklist were designed to be implemented in sequence during
the management of ACS patients. First, a printed reminder
(“Chest Pain” label) was attached to the clinical evaluation form.
This reminder serves as a rapid triage tool upon patient arrival in
the ED (Figure 2). Second, once a patient has been given a
potential diagnosis of ACS, the nurse gave the attending ED
physician the clinical evaluation form with the “Chest Pain”
label and an attached checklist (Figure 3). The checklist contains
an algorithm for risk stratiﬁcation (based on clinical presenta-
tion, ECG analysis, and cardiac enzymes) and recommended
evidence-based therapies for each risk category. The algorithm
divides patients into 3 color categories: red for patients with ST-
segment elevation ACS, yellow for patients with non–ST-segment
Figure 3
Checklist of study procedures.
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cardiac enzymes. The checklist requires that the attending
physician check and conﬁrm the use (or no use in case of
contraindications) of all suggested evidence-based interventions.
Finally, once patients have been classiﬁed into 1 of the 3 catego-
ries, they received a colored bracelet (red, yellow, or green)
according to the risk stratiﬁcation category (Figure 4). This
bracelet helps to promptly identify ACS patients in the ED to avoid
delays in initiating recommended evidence-based therapies.
Case manager. A trained nurse who works at the hospital
(in the ED or coronary care unit) acted as a case manager and
followed up all patients during their hospital stay. The role of the
case manager includes interacting with physicians once gaps in
the incorporation of evidence-based interventions are identiﬁed,
ensuring that all components of the quality improvement
intervention are being used for every ACS patient, identifying
barriers for the implementation of the quality improvement
tools and consequently of evidence-based therapies, and
continuous training of health care staff involved with the care
of ACS patients.
Educational materials
We provided educational materials for all clusters randomized
to the experimental group, including pocket guidelines, an
interactive Web site containing presentations about ACS,
instructional videos on how to implement the quality improve-
ment intervention, and posters containing evidence-based
recommendations for the management of ACS to be displayed
in the ED, coronary care unit, and clinical wards.
Outcomes
An independent, blinded clinical events committee adjudicat-
ed all suspected primary and secondary outcomes based on
standardized and predeﬁned deﬁnitions.
The primary end point was 100% adherence to evidence-
based therapies (aspirin; clopidogrel; anticoagulation with
enoxaparin, unfractionated heparin, or fondaparinux; andstatins), in patients without contraindications, during the ﬁrst
24 hours. Secondary outcomes included individual components
of the primary combined end point (prescription rate of each of
the evidence-based medications during the ﬁrst 24 hours);
prescription rates of aspirin, β-blockers, statins, and angiotensin-
converting enzyme inhibitors (in combination and individually)
at discharge; combined end point of 100% adherence to
evidence-based therapies (acute and discharge); reperfusion
rates for patients with STEMI and 100% adherence to evidence-
based therapies for patients with STEMI (aspirin, reperfusion,
clopidogrel, anticoagulation, and statins) during the ﬁrst 24
hours; major cardiovascular events, including a combined end
point of cardiovascular mortality, nonfatal MI, nonfatal cardiac
arrest, and nonfatal stroke at discharge and at 30 days; all-cause
mortality during the initial hospitalization and at 30 days; and
major bleeding (in-hospital). The following deﬁnitions were
used for clinical outcomes:
• Mortality: Classiﬁed as being cardiovascular or nonvascular
because of other speciﬁed causes (or of unknown etiology).
Cardiovascular death is deﬁned as any death with a vascular
cause and includes death after an MI, cardiac arrest, stroke,
cardiac revascularization procedure (ie, percutaneous coro-
nary intervention or coronary artery bypass graft surgery),
pulmonary embolus, hemorrhage, or death caused by an
unknown cause. Nonvascular death is deﬁned as any death
caused by a clearly documented nonvascular cause (eg,
trauma, infection, malignancy).
• Myocardial infarction: Patients had to fulﬁll at least 2 of the
following: (1) typical prolonged severe chest pain or related
symptoms or signs (eg, ST-segment changes of T-wave
inversion on ECG) suggestive of MI; (2) elevation of troponin
or creatine kinase–MB tomore than the upper limit of normal,
or if creatine kinase–MB was elevated at baseline, reelevation
of at least 50% above the previous level; (3) development of
signiﬁcant Q waves in at least 2 adjacent ECG leads.
• Stroke: Deﬁned as an acute onset of a focal neurologic deﬁcit
of presumed vascular origin lasting for≥24 hours or resulting
Figure 4
Patient bracelet.
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unknown cause (based on computed tomographic or
magnetic resonance scanning or autopsy). Fatal stroke is
deﬁned as death from any cause within 30 days of stroke.
• Nonfatal cardiac arrest: Deﬁned as successful resuscitation
from either documented or presumed ventricular ﬁbrillation,
sustained ventricular tachycardia, asystole, or pulseless
electrical activity requiring cardiopulmonary resuscitation,
pharmacologic therapy, or cardiac deﬁbrillation.
• Major bleeding: Deﬁned as a decrease in hemoglobin levels
of≥20 g/L (2 g/dL) or more, a blood transfusion requiring≥2
U of whole blood or red cells, intracerebral bleeding,
retroperitoneal bleeding, pericardial bleeding, bleeding into
a major joint, bleeding into the eye, and fatal bleeding.
Sample size
Weperformed a prerandomization survey at participating sites
and found that the primary end point rates were in the range of
40%. To detect a 20% improvement in the prescription of 100%
evidence-based therapies within the ﬁrst 24 hours (primary end
point), considering 80% power, 5% signiﬁcance level, and an
intracluster correlation coefﬁcient of 0.21 (value based on a
prerandomization pilot phase), we needed to randomize at least
34 clusters and approximately 1,020 patients (considering a
median of 30 ACS patients per cluster). The ﬁnal population
enrolled in the BRIDGE-ACS was 1,150 patients from 34 clusters.
Statistical analysis plan
All analyses will follow the intention-to-treat principle.
Baseline characteristics will be analyzed to evaluate cluster
imbalances between treatment and control groups and toidentify possible control variables to be included in the ﬁnal
models.16,17 Continuous variables with normal distribution will
be summarized using mean and SD, and those with skewed
distribution will be described using median and 25th and 75th
percentiles. Dichotomous variables will be described by pro-
portions. All estimates at the cluster or patient level will be
weighted by the number of clusters and the number of patients
in each cluster.
Comparisons between groups at the cluster level will be
conducted using the Student t test or Mann-Whitney U test
(when appropriate) for continuous variables and the χ2 or
Fisher exact test for comparisons of proportions. For variables
with skewed distribution, a logarithmic transformation will be
used, and all tests will be weighted by the number of patients at
each cluster. Comparisons between the intervention and
control groups at the patient level will be done using a
generalized estimation equation for modeling proportions and
quantitative variables, taking into account the dependence
between observations within a cluster. The intervention effects
will be expressed as a population average odds ratio in the case
of qualitative variables or the mean difference in the case of
quantitative variables, both with 95% CIs. The effect of
intervention on cardiovascular events at discharge and mortality
at 30 days will be illustrated by Kaplan-Meier curves and
compared using proportional hazards Cox models accounting
for dependence between patients from the same cluster (shared
γ frailty models). A sensitivity analysis will be performed
including patients with contraindications for evidence-based
therapies in the denominator of the overall population.
Subgroup analysis of the primary end point of the trial among
patients with ST-segment elevation and non–ST-segment eleva-
tion will also be performed. All analyses will be conducted using
STATA SE 11 for Windows (STATA Corp LP, College Station,
TX)18 or R 2.13 software.19 No interim analyses will be
performed. The main statistical analyses will be performed by
the Research Institute HCor and validated by the Duke Clinical
Research Institute (Durham, NC).
Ethical considerations
This study was conducted in accordance with the Declaration
of Helsinki and good clinical practice guidelines. All participat-
ing clusters submitted the study protocol for approval by their
research ethics board; written consent was obtained at the
cluster level. This is a common and well-accepted approach; the
objective of such an approach is to avoid selection bias that may
arise from different consent refusals rates between clusters.20
Organizational structure
The BRIDGE-ACS trial was led by an academic steering
committee composed of 2 co-chairs and 1 principal investigator
(see online Appendix). This committee provided scientiﬁc
direction and input, addressed policy issues regarding the
protocol, and met periodically to assess the trial progress. The
executive committee is composed of a subset of senior leaders
from the steering committee. This committee was responsible
for evaluating the progress and safety of the trial and made any
decisions regarding early termination or continuation of the trial.
The trial was conducted by 2 coordinating centers: the
Research Institute HCor and the Brazilian Clinical Research
Institute, both in Sao Paulo, Brazil. The Duke Clinical Research
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main results. Some of the coordinating centers' activities include
selecting and training trial centers; assisting trial centers with
regulatory submissions; distributing and supplying study sites
with the tools and forms, if appropriate; monitoring recruitment
and follow-up at trial centers; data management, testing, and
maintenance of the electronic data capture system, and data
quality control; and data analysis.
Data collection, quality control, and clinical data
management system. In all participating clusters, data will
be collected prospectively by a trained independent health
professional not involved in the care of ACS patients. Data will be
entered using an electronic Web-based data capture system
developed on a Microsoft SQL (Microsoft Corp, Redmond, WA)
platform by a team of programmers at the Research Institute
HCor. Data quality control will be guaranteed by automated data
entry checks, weekly contact with investigators, on-site moni-
toring, and central statistical monitoring.21 General feedbackwill
be provided at investigator meetings and in periodic newsletters.
This trial is registered at clinicaltrials.gov (NCT00958958).14
Funding for this study was provided by the Brazilian Ministry of
Health (Projeto Hospitais de Excelencia a Serviço do SUS–
PROADI). The authors are solely responsible for the design and
conduct of this study, all study analyses, the drafting and editing
of the manuscript, and its ﬁnal contents.
Discussion
Previous studies using a before-after design9,22,23 have
shown absolute improvements in the uptake of evidence-
based therapies of 5% to 15%. Before-after studies are
superior to observational studies; however, they may be
prone to limitations because secular trends or sudden
changes make it difﬁcult to attribute observed changes to
the intervention.13 Furthermore, in such studies, the
intervention is confounded by the Hawthorne effect,
which could lead to an overestimate of the effectiveness
of an intervention. To prevent such types of bias, cluster-
randomized trials are recommended as the optimal design
for evaluating quality improvement interventions. In
addition, cluster-randomized trials allow adequate control
of contamination, which would be challenging in a trial
with randomization at the patient level. Previous cluster-
randomized studies24–26 in the setting of ACS using
different quality improvement tools have had mixed
results, and none evaluated clinical end points or were
conducted in emerging economies and developing
countries, where approximately 80% of the health care
burden is attributable to cardiovascular diseases. In
addition, educational programs such as the one tested
in the BRIDGE-ACS trial can be expensive. Thus, studying
these interventions to prove that they can work is
necessary to sustain them. Finally, if the quality improve-
ment interventions tested in our study are not effective,
then more intensive efforts, with more associated costs,
would be necessary to improve patient care.
In summary, validated quality improvement programs
represent an important way to bridge the gap betweenresearch evidence and clinical practice. If proven
effective, the multifaceted intervention proposed in the
BRIDGE-ACS trial can become a routine part of clinical
practice to maximize the use of evidence-based in-
terventions for the management of ACS.
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Conceição, Porto Alegre, Rio Grande do Sul: Justo Antero
Saiao Lobato Leivas, João Albino Potrich, Luciano Ceolin
Rosa, Karine Franque Lemos, Maria Isabel M B de
Menezes; Hospital de Clínicas de Porto Alegre, Porto
Alegre, Rio Grande do Sul: Carisi Anne Polanczyk, Marianamento Reestinga, Porto Alegre, Rio Grande do Sul:
Leonardo Grillo, Guilherme Verdum Silveira Netto, Celita
Fraporti; Hospital de Clínicas de Uberlândia, Uberlândia,
Minas Gerais: Elmiro Santos Resende, Luzmar de Paula
Faria, Luciano Martins da Silva, Daltro Catani Filho,
Gabriela Freitas Riva, Rômmel M L Costa; Hospital
Regional do Paranoá e Hospital de Base do Distrito
Federal, Paranoá e Brasília, Distrito Federal: Janaina Ramos
de Miranda, Renato David da Silva, Elzir Nascimento da
Silva; Hospital Municipal de Urgência e Emergência Dr.
Clementino Moura, São Luis, Maranhão: Manuela Veigas
Dias Rocha; Hospital Regional do Mato Grosso do Sul,
Campo Grande, Mato Grosso do Sul: Alexandre Frizzo,
Jackon Duarte, Christiano Pereira, Juliana Morinigo, Ana
Maria Thimóteo da Silva;Hospital Pronto Socorro Dr João
Lúcio Pereira Machado, Manaus, Amazonas: Alexandre
Bichara, Marcelo de Souza Ferreira, Jéssica Lisla Rodrigues
Moura, Raquel Ferreira Freitas; Hospital de Urgências de
Teresina, Teresina, Piauí: Dr Gilberto Albuquerque,
Justivan Sérgio Leal Teixeira, Bruno de Andrade Silva;
Hospital Monsenhor Walfredo Gurgel, Natal, Rio Grande
do Norte: Hélida Maria Bezerra, Gustavo Marques de
Medeiros, Waldilene Rodrigues Ferreira, Maria das Graças
Leite Rebouças, João Carlos Leite Rebouças; Hospital Dr
José Pedro Bezerra, Natal, Rio Grande do Norte: Damião
Nobre de Medeiros, Laerte Paiva de Castro, Elisabete
Carrasco, Helia Maria da Silva; Hospital Regional Dr
Deoclécio Marques de Lucena, Parnamirim, Rio Grande
do Norte: Sulamita Osório da Silva Lucena, Helia Maria da
Silva; Hospital Geral de Roraima, Boa Vista, Roraima:
Marcelo Nakashima, Denise Moreth de Santana, Julio
Meneses Osório, Gustavo Ubirajara Marques, Aurivan
Dantas; Hospital de Clínicas Gaspar Vianna e Hospital
de Pronto Socorro Municipal Humberto Maradei
Pereira, Belém, Pará: Helder Reis, Roberta Bentes; Hospi-
tal de Urgências de Goiânia e Hospital Geral de Goiânia,
Goiânia, Goiás: Stanley Silvano Sousa, Andre Luiz Braga das
Dores, Neusilma Rodrigues, Katiuscia Christiane Freitas,
Huark Douglas Correia; Hospital Municipal Pronto
Socorro de Cuiabá—Fundação Saúde de Cuiabá e
Hospital Geral Universitário, Cuiabá, Mato Grosso: Ali
Kassen Omais, Haitham Ahmad, Benedito Elio Ramalho
dos Santos, Gilmar Antonio Coelho Damin; Hospital e
Pronto Socorro João Paulo II, Porto Velho, Rondônia:
Franklin Almeida Lima, Patrícia Alencar de Medeiros
Pereira, Dayane Gonçalves Trindade; Hospital Geral de
Clínicas de Rio Branco,Rio Branco, Acre: Giovani Casseb,
Jorge Escalante, Rosicley Souza da Silva; Sociedade
Hospitalar Angelina Caron, Campina Grande do Sul,
Paraná: Dalton Bertolim Precoma, Giovani Sehn Scopel;
Hospital Regional de Presidente Prudente, Presidente
Prudente, São Paulo: Margaret Assad Cavalcante, Henri-
que Ebaid, Priscila Vicentin; Santa Casa de Votuporanga,
Votuporanga, São Paulo: Mauro Esteves Hernandes,
Chaudes Ferreira da Silva Junior, Vinicius Luis Almeida.
